We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to ...

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

Eli Lilly is escalating its legal push to protect the exclusivity of its high-profile weight-loss and diabetes drugs, ...

Hims shares gained as much as 14% in New York, their biggest gain since Feb. 19.

compounding pharmacy plaintiffs argued that the FDA arbitrarily removed Eli Lilly’s weight loss drug tirzepatide from the drug shortage list. The compounding pharmacies sought a preliminary ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

But unlike those three medications, Eli Lilly's pill is not a peptide medication ... It is unclear whether orforglipron will have a hefty list price similar to those of the injections, which ...

The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Eli Lilly's Alzheimer's treatment is approved for use in the U.S. but the European Medicines Agency recommended against the approval of the drug on Thursday. Indiana-based pharmaceutical company Eli ...

Eli Lilly is suing two pharmacies ... and Mounjaro are off the FDA's shortage list. And they could provide a roadmap for Novo Nordisk, whose obesity drug Wegovy and diabetes treatment Ozempic ...